Understanding the Burden of ACC Through the Eyes of Patients

Status Completed

Clinical Trial Summary

Clinical Trial Description

This is a comprehensive, cross-sectional study conducted with approximately 40-60 individuals affected by ACC who may know the results of molecular profiling of their tumor. Primary Objectives: - To identify the specific burdens faced by patients with ACC - To compare/contrast the burdens faced by patients with ACC at different disease stages (no evident disease, metastatic disease/watchful waiting, progressive disease) Secondary Objectives: - To assess QoL implication in patients living with ACC (Adenoid Cystic Carcinoma) - To compare the burdens and QoL impacts in people living with ACC, with their tumors bearing Notch mutations or Notch Wild Type due to: - Rate of disease progression - Location of Metastases ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04706845
Study type	Observational
Source	Ayala Pharmaceuticals, Inc,
Contact
Status	Completed
Phase
Start date	January 11, 2021
Completion date	August 16, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04973683` - AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer	Phase 1
Completed	`NCT01417143` - Dovitinib in Adenoid Cystic Carcinoma	Phase 2
Recruiting	`NCT04140526` - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC	Phase 1/Phase 2
Active, not recruiting	`NCT05010629` - 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma	Phase 2
Recruiting	`NCT04801264` - Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617	Early Phase 1
Completed	`NCT03319641` - PSMA-PET Imaging for Advanced ACC/SDC	N/A
Recruiting	`NCT02942693` - Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma	Phase 2
Completed	`NCT00581360` - Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck	Phase 2
Not yet recruiting	`NCT05553782` - Drug Screening Using Novel IMD in ACC and Salivary Cancers	Early Phase 1
Completed	`NCT04291300` - Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients	Phase 2
Active, not recruiting	`NCT02775370` - A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck	Phase 2
Active, not recruiting	`NCT02780310` - Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma	Phase 2
Completed	`NCT04119453` - A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)	Phase 2
Active, not recruiting	`NCT02098538` - Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma	Phase 2
Completed	`NCT01558661` - Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma	Phase 2
Completed	`NCT01524692` - Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma	Phase 2
Recruiting	`NCT03556228` - Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma	Phase 1
Recruiting	`NCT01192087` - Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy	Phase 1/Phase 2
Recruiting	`NCT04209660` - Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers	Phase 2
Recruiting	`NCT05774899` - CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC	Phase 1/Phase 2